Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPD | P32754 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103195 | 1.00 | HTR7 (0.46) | HTR7ALPLTDO2IDO2TP53 | |
| SCHEMBL23958205 | 0.89 | TDO2 (0.48) | TDO2IDO2L3MBTL1 | |
| SCHEMBL30103212 | 0.89 | TDO2 (0.48) | TDO2IDO2L3MBTL1 | |
| SCHEMBL30103275 | 0.88 | TDO2 (0.48) | TDO2IDO2TP53LMNAL3MBTL1 | |
| SCHEMBL23958208 | 0.88 | TDO2 (0.48) | TDO2IDO2TP53LMNAL3MBTL1 | |
| SCHEMBL23958262 | 0.86 | — | — | |
| SCHEMBL30103230 | 0.86 | — | — | |
| SCHEMBL23958265 | 0.86 | PIK3CD (0.46) | TDO2IDO2POLB | |
| SCHEMBL29738614 | 0.86 | PIK3CD (0.46) | TDO2IDO2POLB | |
| SCHEMBL24110985 | 0.85 | G6PD (0.50) | HTR7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427399-A | 2-heteroarylaminoquinazolinone derivatives | 住友制药株式会社 | 2022-12-02 | — | — | CN | disclosed |
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | HTR7 1211/4885ALPL 4100/4885TDO2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.